We have located links that may give you full text access.
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Urologic Nursing 2007 April
There are no national guidelines when comparing an aspirin daily to a statin drug in individuals with no history of a cardiovascular event (primary prevention). However, recent reviews of the medical clinical research on statins and aspirin for preventing a first coronary heart disease (CHD) event concluded that compared to no treatment, aspirin is cheaper and has more of an impact in middle-aged men whose 10-year risk for CHD is 7.5% or higher, and adding a statin to aspirin therapy is better in terms of cost effectiveness when a patient's 10-year CHD risk before any treatment is greater than 10%. However, when scrutinizing these data it seems that statins beat aspirin in every single risk-reduction category, and has equal to perhaps less side effects, but a statin costs more. In addition, patients should be informed about the recent observational data suggesting that statins may reduce mortality from other causes such as prostate cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app